This better be a prelude to liquidating the company, or I am going to be even MORE angry. Why the heck do we need a new fat paycheck when the company is making nothing, no plans to make anything, and living off daddy's bankroll (spinoff cash). I guess I will never invest in a Utah company again.
Why don't you leave already twelvetooth? What is the most intelligent thing you have ever posted? "Azixa is not dead"? (the CEO says it is). "Hobden is brilliant"? (he is a total business moron who drove this company into the tank). "Something is afoot" (fascinating post) You have been part of the problem, not the solution. Why don't you take a long hike in Moab and mysteriously get lost.
I listened to the latest presentation (Q&A not webccast). It sure sounded like the new business plan is to license the entire pipeline and get out of the research business. That would make the CFO a key player.
I'd be pitching Azixa mostly to Roche; a combination with Avastin looks extremely attractive in principle (but very expensive to develop). Of the active programs, I'd be pushing hardest to license the metabolism inhibitor: the other two have the potential to become a lot more valuable than they presently are with a little more research.
This train wreck makes me appreciate Incyte a lot more. Their stock is way off, but starting from the same sort of discovery program, and with a lot less seed money, they're getting two drugs to market [almost] for sure. The key seems to be that their technical leader is almost as good a money guy as the real money guys.